"So if RVX is not included in the AHA late breaking presentations announced next week,... it is definite that we will NOT preseng there,... or is it still possible,...?"

Still possible, in my opinion, based upon what happened at ESC 2019. ESC added the DAPA-HF trial to the hotline session schedule (similar to late breaking abstracts) only about 10 days prior to the ESC conference starting. The main slate of hot line presentations were announced on June 22nd. It is uncommon for these late additions, but not impossible.

https://www.medscape.com/viewarticle/917046

"AstraZeneca released the top-line results from the Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure (DAPA-HF) trial in advance of a more comprehensive report. The European Society of Cardiology subsequently announced the study will be presented in a hotline session that has been added to next week's ESC Congress in Paris."

BearDownAZ